Clients entrust CMIC with conducting clinical trials in a wide range of fields, and the resulting depth of experience has helped to develop an outstandingly capable staff. The following table outlines our therapeutic experience. Project coordinators are proficient in English, ensuring that the exchange of detailed case information is smooth and reliable
| I-1. Central nervous system drugs | Dementia of the Alzheimer type Depression Parkinson's disease Major depression Intractable epilepsy Sleeplessness Insomnia Cold Migraine Degenerative arthritis Chronic rheumatoid arthritis |
|---|---|
| I-3. Sensory organ drugs | Oral dryness associated with Sjogren's syndrome Chronic sinusitis |
| II-1. Cardiovascular drugs | High cholesterol Hypertension Diabetic nephropathy Arrhythmia |
| II-2. Respiratory drugs | Bronchial asthma |
| II-3. Gastrointestinal drugs | Patients treated with anticancer drugs Acute gastritis |
| II-4. Hormones | Menopausal disorder and ovarian deficiency symptom Dwarfism Central precocious puberty |
| II-5. Urogenital and anal drugs | Lower urinary tract diseases Prostatomegaly Pollakiuria and incontinence |
| II-6. External skin drugs | Atopic dermatitis Periodontal diseases Skin diseases |
| III-1. Vitamins | For improvement of pollakiuria |
| III-3. Blood and fluid drugs | Hemodialysis Patients with chronic renal failure before dialysis Cerebral infarction Patients with pre-ESRD (end-stage renal disease) |
| III-9. Other metabolic drugs | Type 2 diabetes Hemodialysis Osteoporosis Diabetic nephropathy |
| IV-2. Antineoplastic drugs | Prostate cancer |
| IV-4. Antiallergic drugs | Atopic dermatitis |
| VI-2. Chemotherapeutic agents | Influenza Uveitis Patients with genital or anal wart Respiratory infection Bacterial pneumonia Patients with pointed condyloma Herpes zoster Tinea unguium Secondary infection due to chronic respiratory disease |
| VI-3. Biological products | Patients with hepatitis C Compensated cirrhosis type C Viral diseases |
| VII-2. Diagnostic agents | Contrast enhancement |
